Article Sidebar

PDF (Tiếng Việt)
Published: 2025-04-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v189i4.3212
Issue
Vol. 189 No. 4 (2025)
Section
Các bài báo
How to Cite
Hoa, N. H., & Thanh, L. C. (2025). 14. Regression rate of endometrial hyperplasia in patients treated by progestin therapy at Tu Du Hospital. Journal of Medical Research, 189(4), 128-137. https://doi.org/10.52852/tcncyh.v189i4.3212

14. Regression rate of endometrial hyperplasia in patients treated by progestin therapy at Tu Du Hospital

Nguyen Hong Hoa, Le Chi Thanh

Main Article Content

Abstract

Endometrial hyperplasia is a gynecological disease that can progress into endometrial cancer without suitable intervention. Besides hysterectomy, medical treatment with progestin is an effective solution. Our study aimed to determine the regression rate and explore factors influencing the hormonal treatment outcome. A total of 238 cases met the study criteria. The average age at diagnosis was 42.39 ± 8.08 years old(range from 19 to 59 years old). Abnormal uterine bleeding was observed in 88.24% (210 cases). There were 222 cases of endometrial hyperplasia without atypia, representing 93.27%, while the remaining 16 cases had atypical cells. The regression rate was 84.45% after 3 months of progestin treatment. The treatment was highly effective to induce regression of endometrial hyperplasia lesions, thus permit uterus preservation.

Article Details

Keywords

Endometrial hyperplasia, progestin

References

1. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. May 2015; 125(5): 1272-1278. doi:10.1097/01.Aog.0000465189.50026.20.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. May-Jun 2024; 74(3): 229-263. doi:10.3322/caac.21834.
3. Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. Feb 2015; 75(2): 135-136. doi:10.1055/s-0034-1396256.
4. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. Oct 2021; 81(10): 1145-1153. doi:10.1055/a-1545-4279.
5. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. Dec 2019; 41(12): 1789-1800. doi:10.1016/j.jogc.2019.03.025.
6. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. Aug 2008; 139(2): 169-75. doi:10.1016/j.ejogrb.2008.02.022.
7. Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. Nov 2011; 159(1): 176-9. doi:10.1016/j.ejogrb.2011.06.025.
8. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. Nov 2013; 28(11): 2966-71. doi:10.1093/humrep/det320.
9. Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. Clin Exp Obstet Gynecol. 2013; 40(1): 122-6.
10. Shen Y, Fang H, Zhang Y, et al. Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia. Heliyon. Dec 2022; 8(12): e12150. doi:10.1016/j.heliyon.2022.e12150.
11. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol. Sep 15 2008; 168(6): 563-70; discussion 571-6. doi:10.1093/aje/kwn168.
12. Karakas LA, Atilgan AO, Akilli H, Kuscu UE, Haberal A, Ayhan A. Nulliparity and postmenopausal status are independent factors of malignancy potential of endometrial intraepithelial neoplasia in polyps. Int J Gynaecol Obstet. Mar 2021; 152(3): 433-438. doi:10.1002/ijgo.13448.
13. Gonthier C, Walker F, Luton D, Yazbeck C, Madelenat P, Koskas M. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol. Apr 2014; 133(1): 33-7. doi:10.1016/j.ygyno.2013.11.007.
14. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. Jun 2013; 121(6): 1165-1171. doi:10.1097/AOG.0b013e31828cb563.
15. Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. Jun 2009; 200(6): 678.e1-6. doi:10.1016/j.ajog.2009.02.032.